COVID-19: for PrEP (emtricitabine with tenofovir disoproxil)
Emtricitabine with tenofovir disoproxil fumarate available for pre-exposure prophylaxis (PrEP) for prevention of HIV infection for people who meet the funding criteria. These changes come into effect on 26 March 2020.
Page last updated: 26 March 2020
Removal of requirement for full STI screen
Until 26 March 2020, the Special Authority required a full STI screen. PHARMAC are waiving this part of the criteria from 26 March 2020 until 30 June 2020.
Due to increased COVID-19 testing, it is impractical to conduct a full STI screen.
These dates will then be reviewed and extended if appropriate.
Prescribers can now apply for Special Authority for PrEP for your patients without conducting a full STI screen.
Some tests are still required
The following tests are still required for funding to be approved:
- Hepatitis B (if the patient is not immune).
Special Authority form update
The Schedule will be updated from 1 April 2020. In the meantime, prescribers can apply on the current form, with the STI screen requirement crossed out.
Send the SA form to firstname.lastname@example.org
Who to contact
If you have questions about this change, email email@example.com
Last updated: 15 April 2020